STAAR Surgical Company (STAA) 10-Year Financial Performance & Capital Metrics

STAA • • Industrial / General

HealthcareMedical InstrumentsOphthalmic Devices & Vision CareContact Lenses & Vision Correction

AboutSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.Show more

Revenue $314M -2.6%
EBITDA -$6M -117.2%
Net Income -$20M -194.7%
EPS (Diluted) -0.41 -195.3%
Gross Margin 76.32% -2.6%
EBITDA Margin -1.82% -117.7%
Operating Margin -4.02% -146.1%
Net Margin -6.44% -197.2%
ROE -5.16% -187.3%
ROIC -3.56% -143.9%
Debt/Equity 0.10 +5.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 15.9%

✗Weaknesses

✗Weak 3Y average ROE of 4.7%
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y15.39%

5Y15.89%

3Y10.85%

TTM-32.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-542.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM-541.48%

ROCE

10Y Avg0.01%

5Y Avg6.77%

3Y Avg5.79%

Latest-2.92%

Peer Comparison

Contact Lenses & Vision Correction

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COOThe Cooper Companies, Inc.	16.13B	82.31	44.02	5.06%	10.08%	4.88%	2.69%	0.34
LUCYInnovative Eyewear, Inc.	8.19M	1.53	-0.29	41.99%	-770.01%	-17.97%
BLCOBausch + Lomb Corporation	6.18B	17.44	-19.38	15.56%	-6.13%	-4.69%		0.75
STAASTAAR Surgical Company	1.04B	20.97	-51.15	-2.64%	-41.79%	-27.24%		0.10
WRBYWarby Parker Inc.	3B	28.33	-166.65	15.16%	0.08%	0.19%	1.16%	0.66

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	77.12M	82.43M	90.61M	123.95M	150.19M	163.46M	230.47M	284.39M	322.42M	313.9M
Revenue Growth %	0.03%	0.07%	0.1%	0.37%	0.21%	0.09%	0.41%	0.23%	0.13%	-0.03%
Cost of Goods Sold+	24.4M	24.06M	26.33M	32.44M	38.23M	45.1M	51.84M	61.01M	69.76M	74.32M
COGS % of Revenue	0.32%	0.29%	0.29%	0.26%	0.25%	0.28%	0.22%	0.21%	0.22%	0.24%
Gross Profit+	52.72M	58.37M	64.28M	91.51M	111.95M	118.36M	178.64M	223.38M	252.65M	239.58M
Gross Margin %	0.68%	0.71%	0.71%	0.74%	0.75%	0.72%	0.78%	0.79%	0.78%	0.76%
Gross Profit Growth %	0.08%	0.11%	0.1%	0.42%	0.22%	0.06%	0.51%	0.25%	0.13%	-0.05%
Operating Expenses+	58.06M	71.02M	67.91M	84.92M	100.1M	111.59M	145.3M	179.58M	224.55M	252.19M
OpEx % of Revenue	0.75%	0.86%	0.75%	0.69%	0.67%	0.68%	0.63%	0.63%	0.7%	0.8%
Selling, General & Admin	43.3M	50.73M	48.8M	62.89M	74.8M	79.67M	111.44M	143.6M	180.15M	198.22M
SG&A % of Revenue	0.56%	0.62%	0.54%	0.51%	0.5%	0.49%	0.48%	0.5%	0.56%	0.63%
Research & Development	14.76M	20.29M	19.12M	22.03M	25.3M	31.92M	33.86M	35.98M	44.4M	53.97M
R&D % of Revenue	0.19%	0.25%	0.21%	0.18%	0.17%	0.2%	0.15%	0.13%	0.14%	0.17%
Other Operating Expenses	0	470K	628K	715K	0	0	0	0	0	0
Operating Income+	-5.34M	-12.65M	-3.63M	6.59M	11.85M	6.77M	33.34M	43.8M	28.1M	-12.61M
Operating Margin %	-0.07%	-0.15%	-0.04%	0.05%	0.08%	0.04%	0.14%	0.15%	0.09%	-0.04%
Operating Income Growth %	0.34%	-1.37%	0.71%	2.82%	0.8%	-0.43%	3.93%	0.31%	-0.36%	-1.45%
EBITDA+	-2.94M	-9.76M	-277K	9.06M	15.55M	9.86M	36.98M	48.31M	33.22M	-5.72M
EBITDA Margin %	-0.04%	-0.12%	-0%	0.07%	0.1%	0.06%	0.16%	0.17%	0.1%	-0.02%
EBITDA Growth %	0.47%	-2.33%	0.97%	33.7%	0.72%	-0.37%	2.75%	0.31%	-0.31%	-1.17%
D&A (Non-Cash Add-back)	2.4M	2.89M	3.35M	2.46M	3.7M	3.1M	3.64M	4.51M	5.12M	6.89M
EBIT	-5.48M	-12.65M	-3.63M	6.59M	11.85M	6.77M	33.34M	43.8M	28.1M	-12.61M
Net Interest Income+	-78K	-112K	-112K	165K	988K	238K	-38K	2.45M	6.99M	5.91M
Interest Income	50K	3K	0	165K	988K	238K	-	2.45M	6.99M	5.91M
Interest Expense	128K	115K	112K	0	0	0	38K	0	0	0
Other Income/Expense	-268K	211K	1.33M	44K	1.17M	1.5M	-2.04M	1.75M	5.6M	3.56M
Pretax Income+	-5.61M	-12.44M	-2.3M	6.64M	13.03M	8.27M	31.3M	45.55M	33.7M	-9.05M
Pretax Margin %	-0.07%	-0.15%	-0.03%	0.05%	0.09%	0.05%	0.14%	0.16%	0.1%	-0.03%
Income Tax+	928K	-315K	-157K	1.67M	-1.02M	2.35M	3.79M	5.89M	12.35M	11.16M
Effective Tax Rate %	1.17%	0.97%	0.93%	0.75%	1.08%	0.72%	0.88%	0.87%	0.63%	2.23%
Net Income+	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	27.51M	39.66M	21.35M	-20.21M
Net Margin %	-0.08%	-0.15%	-0.02%	0.04%	0.09%	0.04%	0.12%	0.14%	0.07%	-0.06%
Net Income Growth %	0.22%	-0.86%	0.82%	3.32%	1.83%	-0.58%	3.65%	0.44%	-0.46%	-1.95%
Net Income (Continuing)	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	27.51M	39.66M	21.35M	-20.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.17	-0.30	-0.05	0.11	0.30	0.12	0.50	0.80	0.43	-0.41
EPS Growth %	0.23%	-0.76%	0.83%	3.11%	1.73%	-0.6%	3.17%	0.6%	-0.46%	-1.95%
EPS (Basic)	-0.17	-0.30	-0.05	0.11	0.32	0.13	0.52	0.83	0.44	-0.41
Diluted Shares Outstanding	39.26M	40.33M	41M	45.26M	46.9M	47.95M	49.46M	49.38M	49.43M	49.13M
Basic Shares Outstanding	38.43M	40.33M	41M	45.16M	44.49M	45.6M	47.21M	47.99M	48.52M	49.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	49.07M	49.91M	53.89M	151.57M	174.67M	216.42M	271.41M	311.72M	365.27M	367.94M
Cash & Short-Term Investments	13.4M	14M	18.52M	103.88M	119.97M	152.45M	199.71M	211.64M	220.73M	230.49M
Cash Only	13.4M	14M	18.52M	103.88M	119.97M	152.45M	199.71M	86.48M	183.04M	144.16M
Short-Term Investments	0	0	0	0	0	0	0	125.16M	37.69M	86.33M
Accounts Receivable	15.68M	16.34M	17.85M	25.95M	32.58M	35.23M	46.56M	65.97M	97.98M	79.26M
Days Sales Outstanding	74.19	72.37	71.92	76.4	79.19	78.67	73.73	84.67	110.92	92.16
Inventory	15.92M	14.82M	13.31M	16.7M	17.14M	18.11M	17.27M	24.16M	35.13M	43.3M
Days Inventory Outstanding	238.16	224.87	184.5	187.92	163.66	146.58	121.64	144.55	183.8	212.68
Other Current Assets	2.23M	2.41M	1.83M	2.07M	453K	4.53M	636K	811K	6.98M	980K
Total Non-Current Assets+	13.88M	15.54M	14.04M	15.77M	32.86M	41M	74.37M	107.09M	123.42M	141.58M
Property, Plant & Equipment	10.1M	11.79M	9.78M	11.45M	25.62M	33.39M	67.73M	81.53M	101.41M	121.78M
Fixed Asset Turnover	7.64x	6.99x	9.27x	10.82x	5.86x	4.90x	3.40x	3.49x	3.18x	2.58x
Goodwill	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M
Intangible Assets	666K	473K	271K	243K	296K	270K	218K	173K	0	0
Long-Term Investments	0	119K	121K	122K	0	0	0	13.9M	11.7M	0
Other Non-Current Assets	617K	653K	846K	887K	751K	608K	822K	957K	3.34M	17.23M
Total Assets+	62.95M	65.44M	67.93M	167.34M	207.52M	257.42M	345.78M	418.82M	488.69M	509.52M
Asset Turnover	1.23x	1.26x	1.33x	0.74x	0.72x	0.64x	0.67x	0.68x	0.66x	0.62x
Asset Growth %	0.07%	0.04%	0.04%	1.46%	0.24%	0.24%	0.34%	0.21%	0.17%	0.04%
Total Current Liabilities+	17.89M	21.07M	19.09M	27.73M	34.48M	41.24M	48.8M	51.72M	65.04M	70.31M
Accounts Payable	6.69M	8.31M	6.03M	6.52M	8.05M	2.82M	8.7M	11.58M	13.56M	16.7M
Days Payables Outstanding	100.09	126.07	83.63	73.4	76.86	22.8	61.25	69.26	70.93	82.04
Short-Term Debt	4.16M	4.28M	4.44M	3.78M	1.83M	1.38M	0	0	0	0
Deferred Revenue (Current)	370K	0	0	1000K	0	1000K	0	0	0	0
Other Current Liabilities	1.96M	2.6M	1.86M	5.99M	11.09M	9.07M	22.41M	21.74M	21.43M	24.28M
Current Ratio	2.74x	2.37x	2.82x	5.47x	5.07x	5.25x	5.56x	6.03x	5.62x	5.23x
Quick Ratio	1.85x	1.67x	2.13x	4.86x	4.57x	4.81x	5.21x	5.56x	5.08x	4.62x
Cash Conversion Cycle	212.26	171.18	172.79	190.93	165.99	202.45	134.12	159.97	223.79	222.81
Total Non-Current Liabilities+	6.22M	6.47M	5.91M	7.18M	13.16M	18.96M	38.42M	30.99M	37.7M	41.88M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	204K	1.34M	531K	459K	4.45M	6.58M	28.65M	27.35M	31.47M	34.81M
Deferred Tax Liabilities	1.89M	881K	350K	1.02M	658K	222K	811K	1.49M	1.08M	297K
Other Non-Current Liabilities	4.13M	4.25M	5.03M	5.7M	8.05M	12.16M	8.96M	2.15M	5.16M	6.78M
Total Liabilities	24.11M	27.54M	25M	34.91M	47.64M	60.19M	87.22M	82.71M	102.74M	112.19M
Total Debt+	4.72M	6.82M	6.25M	5.34M	9.54M	10.8M	32.06M	31.04M	35.83M	38.74M
Net Debt	-8.68M	-7.18M	-12.27M	-98.54M	-110.43M	-141.65M	-167.65M	-55.44M	-147.2M	-105.42M
Debt / Equity	0.12x	0.18x	0.15x	0.04x	0.06x	0.05x	0.12x	0.09x	0.09x	0.10x
Debt / EBITDA	-	-	-	0.59x	0.61x	1.09x	0.87x	0.64x	1.08x	-
Net Debt / EBITDA	-	-	-	-10.88x	-7.10x	-14.36x	-4.53x	-1.15x	-4.43x	-
Interest Coverage	-41.70x	-110.04x	-32.42x	-	-	-	877.34x	-	-	-
Total Equity+	38.85M	37.91M	42.94M	132.43M	159.88M	197.22M	258.56M	336.11M	385.95M	397.33M
Equity Growth %	0.05%	-0.02%	0.13%	2.08%	0.21%	0.23%	0.31%	0.3%	0.15%	0.03%
Book Value per Share	0.99	0.94	1.05	2.93	3.41	4.11	5.23	6.81	7.81	8.09
Total Shareholders' Equity	38.85M	37.91M	42.94M	132.43M	159.88M	197.22M	258.56M	336.11M	385.95M	397.33M
Common Stock	399K	407K	414K	442K	448K	464K	477K	482K	488K	493K
Retained Earnings	-146.98M	-159.11M	-161.25M	-156.28M	-141.8M	-135.89M	-111.39M	-68.72M	-47.37M	-67.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.58M	-1.05M	-1.15M	-1.32M	-3.05M	-5.54M	-4.05M	156K	-4.11M	-7.03M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.16M	1.05M	2.85M	12.77M	25.8M	20.95M	43.96M	35.72M	14.59M	15.72M
Operating CF Margin %	-0.03%	0.01%	0.03%	0.1%	0.17%	0.13%	0.19%	0.13%	0.05%	0.05%
Operating CF Growth %	0.73%	1.49%	1.72%	3.47%	1.02%	-0.19%	1.1%	-0.19%	-0.59%	0.08%
Net Income	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	27.51M	39.01M	21.35M	-20.21M
Depreciation & Amortization	2.4M	2.89M	3.35M	2.46M	3.7M	3.1M	3.64M	4.51M	5.12M	6.89M
Stock-Based Compensation	3.3M	8.56M	3.16M	6.76M	10.55M	12.15M	14.61M	20.37M	23.52M	27.21M
Deferred Taxes	473K	-1.36M	-547K	441K	-3.48M	-849K	-1.51M	-1.34M	3.26M	3.59M
Other Non-Cash Items	478K	918K	3.01M	2.62M	2.23M	3.41M	2.11M	2.3M	2.18M	3.64M
Working Capital Changes	-2.29M	2.17M	-3.99M	-4.49M	-1.25M	-2.76M	-2.39M	-29.13M	-40.84M	-5.4M
Change in Receivables	-4.89M	-771K	-1.86M	-6.04M	-4.5M	-3.97M	-8.87M	-19.6M	-32.76M	16.49K
Change in Inventory	327K	1.82M	312K	-4.19M	-950K	-1.39M	66K	-7.94M	-14.36M	-10K
Change in Payables	14K	1.01M	-2.5M	243K	1.08M	-1.2M	108K	1.8M	-701K	75
Cash from Investing+	-2.04M	-3.21M	-1.05M	-2.25M	-10.18M	-8.4M	-13.64M	-156.38M	74.35M	-59.22M
Capital Expenditures	-2.04M	-3.21M	-1.05M	-2.25M	-10.1M	-8.4M	-13.64M	-18.11M	-18.19M	-23.39M
CapEx % of Revenue	0.03%	0.04%	0.01%	0.02%	0.07%	0.05%	0.06%	0.06%	0.06%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2K	0	0	0	-83K	0	0	-138.27M	0	0
Cash from Financing+	4.58M	2.95M	2.44M	74.64M	149K	19.57M	17.79M	8.3M	7.42M	5.72M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.97M	2.44M	3.97M	76.6M	3.46M	20.65M	19.44M	8.42M	9.67M	7.39M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.21M	-2.16M	1.81M	10.52M	15.62M	12.55M	30.32M	17.61M	-3.59M	-7.67M
FCF Margin %	-0.05%	-0.03%	0.02%	0.08%	0.1%	0.08%	0.13%	0.06%	-0.01%	-0.02%
FCF Growth %	0.65%	0.49%	1.84%	4.82%	0.48%	-0.2%	1.42%	-0.42%	-1.2%	-1.13%
FCF per Share	-0.11	-0.05	0.04	0.23	0.33	0.26	0.61	0.36	-0.07	-0.16
FCF Conversion (FCF/Net Income)	0.33x	-0.09x	-1.33x	2.57x	1.84x	3.54x	1.60x	0.90x	0.68x	-0.78x
Interest Paid	0	0	0	0	0	0	75K	52K	75K	87K
Taxes Paid	0	0	0	0	0	0	7.47M	6.63M	2.84M	10.98M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-17.2%	-31.61%	-5.29%	5.67%	9.61%	3.31%	12.07%	13.34%	5.91%	-5.16%
Return on Invested Capital (ROIC)	-13.51%	-31.17%	-8.87%	15.33%	21.33%	9.67%	34.14%	17.68%	8.11%	-3.56%
Gross Margin	68.36%	70.81%	70.94%	73.83%	74.54%	72.41%	77.51%	78.55%	78.36%	76.32%
Net Margin	-8.47%	-14.71%	-2.36%	4.01%	9.35%	3.62%	11.94%	13.95%	6.62%	-6.44%
Debt / Equity	0.12x	0.18x	0.15x	0.04x	0.06x	0.05x	0.12x	0.09x	0.09x	0.10x
Interest Coverage	-41.70x	-110.04x	-32.42x	-	-	-	877.34x	-	-	-
FCF Conversion	0.33x	-0.09x	-1.33x	2.57x	1.84x	3.54x	1.60x	0.90x	0.68x	-0.78x
Revenue Growth	2.85%	6.88%	9.92%	36.8%	21.16%	8.84%	41%	23.39%	13.37%	-2.64%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Implantable Collamer Lenses	51.54M	59.11M	68.33M	101.08M	129.32M	141.41M	212.91M	269.71M	319.43M	312.54M
Implantable Collamer Lenses Growth	-	14.68%	15.59%	47.94%	27.94%	9.34%	50.56%	26.68%	18.43%	-2.16%
Other Surgical Products	5.72M	3.62M	5.03M	6.68M	5.17M	8.48M	5.05M	5.04M	1.85M	1.36M
Other Surgical Products Growth	-	-36.83%	39.09%	32.84%	-22.53%	63.88%	-40.46%	-0.14%	-63.32%	-26.55%
Cataract Intraocular Lenses	-	-	-	-	-	-	12.52M	9.64M	1.14M	-
Cataract Intraocular Lenses Growth	-	-	-	-	-	-	-	-23.01%	-88.18%	-
Intraocular Lenses	19.86M	19.71M	17.26M	16.19M	15.69M	13.57M	-	-	-	-
Intraocular Lenses Growth	-	-0.76%	-12.42%	-6.17%	-3.11%	-13.48%	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Countries	22.99M	31.77M	35.87M	47.42M	-	-	-	-	-	-
Other Countries Growth	-	38.20%	12.90%	32.19%	-	-	-	-	-	-
CHINA	12.57M	16.02M	23.88M	46.07M	-	-	-	-	-	-
CHINA Growth	-	27.43%	49.08%	92.91%	-	-	-	-	-	-
JAPAN	16.98M	17.33M	17.42M	23.15M	-	-	-	-	-	-
JAPAN Growth	-	2.04%	0.55%	32.87%	-	-	-	-	-	-
UNITED STATES	10.9M	9.86M	7.89M	7.32M	-	-	-	-	-	-
UNITED STATES Growth	-	-9.58%	-19.93%	-7.32%	-	-	-	-	-	-
KOREA, REPUBLIC OF	8.06M	7.46M	5.54M	-	-	-	-	-	-	-
KOREA, REPUBLIC OF Growth	-	-7.52%	-25.65%	-	-	-	-	-	-	-
SPAIN	5.62M	-	-	-	-	-	-	-	-	-
SPAIN Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

STAAR Surgical Company (STAA) reported $230.6M in revenue for fiscal year 2024. This represents a 267% increase from $62.8M in 2011.

STAAR Surgical Company (STAA) saw revenue decline by 2.6% over the past year.

STAAR Surgical Company (STAA) reported a net loss of $96.4M for fiscal year 2024.

Dividend & Returns

STAAR Surgical Company (STAA) has a return on equity (ROE) of -5.2%. Negative ROE indicates the company is unprofitable.

STAAR Surgical Company (STAA) had negative free cash flow of $39.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

STAAR Surgical Company (STAA) 10-Year Financial Performance & Capital Metrics

STAA • • Industrial / General

HealthcareMedical InstrumentsOphthalmic Devices & Vision CareContact Lenses & Vision Correction

Revenue $314M -2.6%
EBITDA -$6M -117.2%
Net Income -$20M -194.7%
EPS (Diluted) -0.41 -195.3%
Gross Margin 76.32% -2.6%
EBITDA Margin -1.82% -117.7%
Operating Margin -4.02% -146.1%
Net Margin -6.44% -197.2%
ROE -5.16% -187.3%
ROIC -3.56% -143.9%
Debt/Equity 0.10 +5.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 15.9%

✗Weaknesses

✗Weak 3Y average ROE of 4.7%
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y15.39%

5Y15.89%

3Y10.85%

TTM-32.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-542.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM-541.48%

ROCE

10Y Avg0.01%

5Y Avg6.77%

3Y Avg5.79%

Latest-2.92%

Peer Comparison

Contact Lenses & Vision Correction

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COOThe Cooper Companies, Inc.	16.13B	82.31	44.02	5.06%	10.08%	4.88%	2.69%	0.34
LUCYInnovative Eyewear, Inc.	8.19M	1.53	-0.29	41.99%	-770.01%	-17.97%
BLCOBausch + Lomb Corporation	6.18B	17.44	-19.38	15.56%	-6.13%	-4.69%		0.75
STAASTAAR Surgical Company	1.04B	20.97	-51.15	-2.64%	-41.79%	-27.24%		0.10
WRBYWarby Parker Inc.	3B	28.33	-166.65	15.16%	0.08%	0.19%	1.16%	0.66

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	77.12M	82.43M	90.61M	123.95M	150.19M	163.46M	230.47M	284.39M	322.42M	313.9M
Revenue Growth %	0.03%	0.07%	0.1%	0.37%	0.21%	0.09%	0.41%	0.23%	0.13%	-0.03%
Cost of Goods Sold+	24.4M	24.06M	26.33M	32.44M	38.23M	45.1M	51.84M	61.01M	69.76M	74.32M
COGS % of Revenue	0.32%	0.29%	0.29%	0.26%	0.25%	0.28%	0.22%	0.21%	0.22%	0.24%
Gross Profit+	52.72M	58.37M	64.28M	91.51M	111.95M	118.36M	178.64M	223.38M	252.65M	239.58M
Gross Margin %	0.68%	0.71%	0.71%	0.74%	0.75%	0.72%	0.78%	0.79%	0.78%	0.76%
Gross Profit Growth %	0.08%	0.11%	0.1%	0.42%	0.22%	0.06%	0.51%	0.25%	0.13%	-0.05%
Operating Expenses+	58.06M	71.02M	67.91M	84.92M	100.1M	111.59M	145.3M	179.58M	224.55M	252.19M
OpEx % of Revenue	0.75%	0.86%	0.75%	0.69%	0.67%	0.68%	0.63%	0.63%	0.7%	0.8%
Selling, General & Admin	43.3M	50.73M	48.8M	62.89M	74.8M	79.67M	111.44M	143.6M	180.15M	198.22M
SG&A % of Revenue	0.56%	0.62%	0.54%	0.51%	0.5%	0.49%	0.48%	0.5%	0.56%	0.63%
Research & Development	14.76M	20.29M	19.12M	22.03M	25.3M	31.92M	33.86M	35.98M	44.4M	53.97M
R&D % of Revenue	0.19%	0.25%	0.21%	0.18%	0.17%	0.2%	0.15%	0.13%	0.14%	0.17%
Other Operating Expenses	0	470K	628K	715K	0	0	0	0	0	0
Operating Income+	-5.34M	-12.65M	-3.63M	6.59M	11.85M	6.77M	33.34M	43.8M	28.1M	-12.61M
Operating Margin %	-0.07%	-0.15%	-0.04%	0.05%	0.08%	0.04%	0.14%	0.15%	0.09%	-0.04%
Operating Income Growth %	0.34%	-1.37%	0.71%	2.82%	0.8%	-0.43%	3.93%	0.31%	-0.36%	-1.45%
EBITDA+	-2.94M	-9.76M	-277K	9.06M	15.55M	9.86M	36.98M	48.31M	33.22M	-5.72M
EBITDA Margin %	-0.04%	-0.12%	-0%	0.07%	0.1%	0.06%	0.16%	0.17%	0.1%	-0.02%
EBITDA Growth %	0.47%	-2.33%	0.97%	33.7%	0.72%	-0.37%	2.75%	0.31%	-0.31%	-1.17%
D&A (Non-Cash Add-back)	2.4M	2.89M	3.35M	2.46M	3.7M	3.1M	3.64M	4.51M	5.12M	6.89M
EBIT	-5.48M	-12.65M	-3.63M	6.59M	11.85M	6.77M	33.34M	43.8M	28.1M	-12.61M
Net Interest Income+	-78K	-112K	-112K	165K	988K	238K	-38K	2.45M	6.99M	5.91M
Interest Income	50K	3K	0	165K	988K	238K	-	2.45M	6.99M	5.91M
Interest Expense	128K	115K	112K	0	0	0	38K	0	0	0
Other Income/Expense	-268K	211K	1.33M	44K	1.17M	1.5M	-2.04M	1.75M	5.6M	3.56M
Pretax Income+	-5.61M	-12.44M	-2.3M	6.64M	13.03M	8.27M	31.3M	45.55M	33.7M	-9.05M
Pretax Margin %	-0.07%	-0.15%	-0.03%	0.05%	0.09%	0.05%	0.14%	0.16%	0.1%	-0.03%
Income Tax+	928K	-315K	-157K	1.67M	-1.02M	2.35M	3.79M	5.89M	12.35M	11.16M
Effective Tax Rate %	1.17%	0.97%	0.93%	0.75%	1.08%	0.72%	0.88%	0.87%	0.63%	2.23%
Net Income+	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	27.51M	39.66M	21.35M	-20.21M
Net Margin %	-0.08%	-0.15%	-0.02%	0.04%	0.09%	0.04%	0.12%	0.14%	0.07%	-0.06%
Net Income Growth %	0.22%	-0.86%	0.82%	3.32%	1.83%	-0.58%	3.65%	0.44%	-0.46%	-1.95%
Net Income (Continuing)	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	27.51M	39.66M	21.35M	-20.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.17	-0.30	-0.05	0.11	0.30	0.12	0.50	0.80	0.43	-0.41
EPS Growth %	0.23%	-0.76%	0.83%	3.11%	1.73%	-0.6%	3.17%	0.6%	-0.46%	-1.95%
EPS (Basic)	-0.17	-0.30	-0.05	0.11	0.32	0.13	0.52	0.83	0.44	-0.41
Diluted Shares Outstanding	39.26M	40.33M	41M	45.26M	46.9M	47.95M	49.46M	49.38M	49.43M	49.13M
Basic Shares Outstanding	38.43M	40.33M	41M	45.16M	44.49M	45.6M	47.21M	47.99M	48.52M	49.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	49.07M	49.91M	53.89M	151.57M	174.67M	216.42M	271.41M	311.72M	365.27M	367.94M
Cash & Short-Term Investments	13.4M	14M	18.52M	103.88M	119.97M	152.45M	199.71M	211.64M	220.73M	230.49M
Cash Only	13.4M	14M	18.52M	103.88M	119.97M	152.45M	199.71M	86.48M	183.04M	144.16M
Short-Term Investments	0	0	0	0	0	0	0	125.16M	37.69M	86.33M
Accounts Receivable	15.68M	16.34M	17.85M	25.95M	32.58M	35.23M	46.56M	65.97M	97.98M	79.26M
Days Sales Outstanding	74.19	72.37	71.92	76.4	79.19	78.67	73.73	84.67	110.92	92.16
Inventory	15.92M	14.82M	13.31M	16.7M	17.14M	18.11M	17.27M	24.16M	35.13M	43.3M
Days Inventory Outstanding	238.16	224.87	184.5	187.92	163.66	146.58	121.64	144.55	183.8	212.68
Other Current Assets	2.23M	2.41M	1.83M	2.07M	453K	4.53M	636K	811K	6.98M	980K
Total Non-Current Assets+	13.88M	15.54M	14.04M	15.77M	32.86M	41M	74.37M	107.09M	123.42M	141.58M
Property, Plant & Equipment	10.1M	11.79M	9.78M	11.45M	25.62M	33.39M	67.73M	81.53M	101.41M	121.78M
Fixed Asset Turnover	7.64x	6.99x	9.27x	10.82x	5.86x	4.90x	3.40x	3.49x	3.18x	2.58x
Goodwill	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M	1.79M
Intangible Assets	666K	473K	271K	243K	296K	270K	218K	173K	0	0
Long-Term Investments	0	119K	121K	122K	0	0	0	13.9M	11.7M	0
Other Non-Current Assets	617K	653K	846K	887K	751K	608K	822K	957K	3.34M	17.23M
Total Assets+	62.95M	65.44M	67.93M	167.34M	207.52M	257.42M	345.78M	418.82M	488.69M	509.52M
Asset Turnover	1.23x	1.26x	1.33x	0.74x	0.72x	0.64x	0.67x	0.68x	0.66x	0.62x
Asset Growth %	0.07%	0.04%	0.04%	1.46%	0.24%	0.24%	0.34%	0.21%	0.17%	0.04%
Total Current Liabilities+	17.89M	21.07M	19.09M	27.73M	34.48M	41.24M	48.8M	51.72M	65.04M	70.31M
Accounts Payable	6.69M	8.31M	6.03M	6.52M	8.05M	2.82M	8.7M	11.58M	13.56M	16.7M
Days Payables Outstanding	100.09	126.07	83.63	73.4	76.86	22.8	61.25	69.26	70.93	82.04
Short-Term Debt	4.16M	4.28M	4.44M	3.78M	1.83M	1.38M	0	0	0	0
Deferred Revenue (Current)	370K	0	0	1000K	0	1000K	0	0	0	0
Other Current Liabilities	1.96M	2.6M	1.86M	5.99M	11.09M	9.07M	22.41M	21.74M	21.43M	24.28M
Current Ratio	2.74x	2.37x	2.82x	5.47x	5.07x	5.25x	5.56x	6.03x	5.62x	5.23x
Quick Ratio	1.85x	1.67x	2.13x	4.86x	4.57x	4.81x	5.21x	5.56x	5.08x	4.62x
Cash Conversion Cycle	212.26	171.18	172.79	190.93	165.99	202.45	134.12	159.97	223.79	222.81
Total Non-Current Liabilities+	6.22M	6.47M	5.91M	7.18M	13.16M	18.96M	38.42M	30.99M	37.7M	41.88M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	204K	1.34M	531K	459K	4.45M	6.58M	28.65M	27.35M	31.47M	34.81M
Deferred Tax Liabilities	1.89M	881K	350K	1.02M	658K	222K	811K	1.49M	1.08M	297K
Other Non-Current Liabilities	4.13M	4.25M	5.03M	5.7M	8.05M	12.16M	8.96M	2.15M	5.16M	6.78M
Total Liabilities	24.11M	27.54M	25M	34.91M	47.64M	60.19M	87.22M	82.71M	102.74M	112.19M
Total Debt+	4.72M	6.82M	6.25M	5.34M	9.54M	10.8M	32.06M	31.04M	35.83M	38.74M
Net Debt	-8.68M	-7.18M	-12.27M	-98.54M	-110.43M	-141.65M	-167.65M	-55.44M	-147.2M	-105.42M
Debt / Equity	0.12x	0.18x	0.15x	0.04x	0.06x	0.05x	0.12x	0.09x	0.09x	0.10x
Debt / EBITDA	-	-	-	0.59x	0.61x	1.09x	0.87x	0.64x	1.08x	-
Net Debt / EBITDA	-	-	-	-10.88x	-7.10x	-14.36x	-4.53x	-1.15x	-4.43x	-
Interest Coverage	-41.70x	-110.04x	-32.42x	-	-	-	877.34x	-	-	-
Total Equity+	38.85M	37.91M	42.94M	132.43M	159.88M	197.22M	258.56M	336.11M	385.95M	397.33M
Equity Growth %	0.05%	-0.02%	0.13%	2.08%	0.21%	0.23%	0.31%	0.3%	0.15%	0.03%
Book Value per Share	0.99	0.94	1.05	2.93	3.41	4.11	5.23	6.81	7.81	8.09
Total Shareholders' Equity	38.85M	37.91M	42.94M	132.43M	159.88M	197.22M	258.56M	336.11M	385.95M	397.33M
Common Stock	399K	407K	414K	442K	448K	464K	477K	482K	488K	493K
Retained Earnings	-146.98M	-159.11M	-161.25M	-156.28M	-141.8M	-135.89M	-111.39M	-68.72M	-47.37M	-67.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.58M	-1.05M	-1.15M	-1.32M	-3.05M	-5.54M	-4.05M	156K	-4.11M	-7.03M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.16M	1.05M	2.85M	12.77M	25.8M	20.95M	43.96M	35.72M	14.59M	15.72M
Operating CF Margin %	-0.03%	0.01%	0.03%	0.1%	0.17%	0.13%	0.19%	0.13%	0.05%	0.05%
Operating CF Growth %	0.73%	1.49%	1.72%	3.47%	1.02%	-0.19%	1.1%	-0.19%	-0.59%	0.08%
Net Income	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	27.51M	39.01M	21.35M	-20.21M
Depreciation & Amortization	2.4M	2.89M	3.35M	2.46M	3.7M	3.1M	3.64M	4.51M	5.12M	6.89M
Stock-Based Compensation	3.3M	8.56M	3.16M	6.76M	10.55M	12.15M	14.61M	20.37M	23.52M	27.21M
Deferred Taxes	473K	-1.36M	-547K	441K	-3.48M	-849K	-1.51M	-1.34M	3.26M	3.59M
Other Non-Cash Items	478K	918K	3.01M	2.62M	2.23M	3.41M	2.11M	2.3M	2.18M	3.64M
Working Capital Changes	-2.29M	2.17M	-3.99M	-4.49M	-1.25M	-2.76M	-2.39M	-29.13M	-40.84M	-5.4M
Change in Receivables	-4.89M	-771K	-1.86M	-6.04M	-4.5M	-3.97M	-8.87M	-19.6M	-32.76M	16.49K
Change in Inventory	327K	1.82M	312K	-4.19M	-950K	-1.39M	66K	-7.94M	-14.36M	-10K
Change in Payables	14K	1.01M	-2.5M	243K	1.08M	-1.2M	108K	1.8M	-701K	75
Cash from Investing+	-2.04M	-3.21M	-1.05M	-2.25M	-10.18M	-8.4M	-13.64M	-156.38M	74.35M	-59.22M
Capital Expenditures	-2.04M	-3.21M	-1.05M	-2.25M	-10.1M	-8.4M	-13.64M	-18.11M	-18.19M	-23.39M
CapEx % of Revenue	0.03%	0.04%	0.01%	0.02%	0.07%	0.05%	0.06%	0.06%	0.06%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2K	0	0	0	-83K	0	0	-138.27M	0	0
Cash from Financing+	4.58M	2.95M	2.44M	74.64M	149K	19.57M	17.79M	8.3M	7.42M	5.72M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.97M	2.44M	3.97M	76.6M	3.46M	20.65M	19.44M	8.42M	9.67M	7.39M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.21M	-2.16M	1.81M	10.52M	15.62M	12.55M	30.32M	17.61M	-3.59M	-7.67M
FCF Margin %	-0.05%	-0.03%	0.02%	0.08%	0.1%	0.08%	0.13%	0.06%	-0.01%	-0.02%
FCF Growth %	0.65%	0.49%	1.84%	4.82%	0.48%	-0.2%	1.42%	-0.42%	-1.2%	-1.13%
FCF per Share	-0.11	-0.05	0.04	0.23	0.33	0.26	0.61	0.36	-0.07	-0.16
FCF Conversion (FCF/Net Income)	0.33x	-0.09x	-1.33x	2.57x	1.84x	3.54x	1.60x	0.90x	0.68x	-0.78x
Interest Paid	0	0	0	0	0	0	75K	52K	75K	87K
Taxes Paid	0	0	0	0	0	0	7.47M	6.63M	2.84M	10.98M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-17.2%	-31.61%	-5.29%	5.67%	9.61%	3.31%	12.07%	13.34%	5.91%	-5.16%
Return on Invested Capital (ROIC)	-13.51%	-31.17%	-8.87%	15.33%	21.33%	9.67%	34.14%	17.68%	8.11%	-3.56%
Gross Margin	68.36%	70.81%	70.94%	73.83%	74.54%	72.41%	77.51%	78.55%	78.36%	76.32%
Net Margin	-8.47%	-14.71%	-2.36%	4.01%	9.35%	3.62%	11.94%	13.95%	6.62%	-6.44%
Debt / Equity	0.12x	0.18x	0.15x	0.04x	0.06x	0.05x	0.12x	0.09x	0.09x	0.10x
Interest Coverage	-41.70x	-110.04x	-32.42x	-	-	-	877.34x	-	-	-
FCF Conversion	0.33x	-0.09x	-1.33x	2.57x	1.84x	3.54x	1.60x	0.90x	0.68x	-0.78x
Revenue Growth	2.85%	6.88%	9.92%	36.8%	21.16%	8.84%	41%	23.39%	13.37%	-2.64%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Implantable Collamer Lenses	51.54M	59.11M	68.33M	101.08M	129.32M	141.41M	212.91M	269.71M	319.43M	312.54M
Implantable Collamer Lenses Growth	-	14.68%	15.59%	47.94%	27.94%	9.34%	50.56%	26.68%	18.43%	-2.16%
Other Surgical Products	5.72M	3.62M	5.03M	6.68M	5.17M	8.48M	5.05M	5.04M	1.85M	1.36M
Other Surgical Products Growth	-	-36.83%	39.09%	32.84%	-22.53%	63.88%	-40.46%	-0.14%	-63.32%	-26.55%
Cataract Intraocular Lenses	-	-	-	-	-	-	12.52M	9.64M	1.14M	-
Cataract Intraocular Lenses Growth	-	-	-	-	-	-	-	-23.01%	-88.18%	-
Intraocular Lenses	19.86M	19.71M	17.26M	16.19M	15.69M	13.57M	-	-	-	-
Intraocular Lenses Growth	-	-0.76%	-12.42%	-6.17%	-3.11%	-13.48%	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Countries	22.99M	31.77M	35.87M	47.42M	-	-	-	-	-	-
Other Countries Growth	-	38.20%	12.90%	32.19%	-	-	-	-	-	-
CHINA	12.57M	16.02M	23.88M	46.07M	-	-	-	-	-	-
CHINA Growth	-	27.43%	49.08%	92.91%	-	-	-	-	-	-
JAPAN	16.98M	17.33M	17.42M	23.15M	-	-	-	-	-	-
JAPAN Growth	-	2.04%	0.55%	32.87%	-	-	-	-	-	-
UNITED STATES	10.9M	9.86M	7.89M	7.32M	-	-	-	-	-	-
UNITED STATES Growth	-	-9.58%	-19.93%	-7.32%	-	-	-	-	-	-
KOREA, REPUBLIC OF	8.06M	7.46M	5.54M	-	-	-	-	-	-	-
KOREA, REPUBLIC OF Growth	-	-7.52%	-25.65%	-	-	-	-	-	-	-
SPAIN	5.62M	-	-	-	-	-	-	-	-	-
SPAIN Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

STAAR Surgical Company (STAA) reported $230.6M in revenue for fiscal year 2024. This represents a 267% increase from $62.8M in 2011.

STAAR Surgical Company (STAA) saw revenue decline by 2.6% over the past year.

STAAR Surgical Company (STAA) reported a net loss of $96.4M for fiscal year 2024.

Dividend & Returns

STAAR Surgical Company (STAA) has a return on equity (ROE) of -5.2%. Negative ROE indicates the company is unprofitable.

STAAR Surgical Company (STAA) had negative free cash flow of $39.5M in fiscal year 2024, likely due to heavy capital investments.